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SH2-Dependent Autophosphorylation within the Tec Family Kinase Itk
Abstract
The Tec family kinase, Itk (interleukin-2 tyrosine kinase), undergoes an in cis autophosphorylation on Y180
within its Src homology 3 (SH3) domain. Autophosphorylation of the Itk SH3 domain by the Itk kinase
domain is strictly dependent on the presence of the intervening Src homology 2 (SH2) domain. A direct
docking interaction between the Itk kinase and SH2 domains brings the Itk SH3 domain into the active site
where Y180 is then phosphorylated. We now identify the residues on the surface of the Itk SH2 domain
responsible for substrate docking and show that this SH2 surface mediates autophosphorylation in the full-
length Itk molecule. The canonical phospholigand binding site on the SH2 domain is not involved in substrate
docking, instead the docking site consists of side chains from three loop regions (AB, EF and BG) and part of
the βD strand. These results are extended into Btk (Bruton's tyrosine kinase), a Tec family kinase linked to the
B-cell deficiency X-linked agammaglobulinemia (XLA). Our results suggest that some XLA-causing
mutations might impair Btk phosphorylation.
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Abstract
The Tec family kinase, Itk, undergoes an in cis autophosphorylation on Y180 within its SH3 domain.
Autophosphorylation of the Itk SH3 domain by the Itk kinase domain is strictly dependent on the
presence of the intervening SH2 domain. A direct docking interaction between the Itk kinase and
SH2 domains brings the Itk SH3 domain into the active site where Y180 is then phosphorylated. We
now identify the residues on the surface of the Itk SH2 domain responsible for substrate docking and
show that this SH2 surface mediates autophosphorylation in the full length Itk molecule. The
canonical phospholigand binding site on the SH2 domain is not involved in substrate docking, instead
the docking site consists of side chains from three loop regions (AB, EF and BG) and part of the
βD strand. These results are extended into Btk, a Tec family kinase linked to the B cell deficiency
X-linked agammaglobulinemia (XLA). Our results suggest that some XLA causing mutations might
impair Btk phosphorylation.
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INTRODUCTION
Tyrosine kinases are enzymes that catalyze the transfer of the gamma phosphate of ATP to a
tyrosine residue within the substrate. Although a large number of tyrosine residues are
accessible for phosphorylation within the cellular milieu, most tyrosine kinases phosphorylate
a limited subset of potential substrates within the cell 1. Substrate selectivity is crucial for the
normal functioning of the cell. However, the mechanisms by which substrate specificity is
achieved by kinases is far from clear 1; 2.
Specific docking mechanisms are emerging as a theme in kinase substrate recognition 1; 2; 3;
4. A docking interaction is defined as a direct interaction between a site on the kinase domain
(remote from the active site) and a complementary site on the substrate (remote from the
phosphorylation site) 3; 4. Docking modules are well characterized for serine/threonine kinases
and consist of short peptide motifs such as the D box of MAPK substrates and the DEF domain
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of ERK substrates 1; 3; 4. While substrate docking interactions are well known for serine/
threonine kinases, they have been less well characterized for tyrosine kinases with only two
specific examples described to date: C-terminal Src kinase (Csk),5; 6; 7 and Tec family kinases
8.
We have previously reported biochemical data that support a substrate docking mechanism for
the Tec kinase family (Itk, Btk, Tec, Bmx and Txk) 8. Using Itk as a model system, we have
shown that Itk autophosphorylation within the Itk SH3 domain (specifically on Y180) is
dependent on the presence of the neighboring Itk SH2 domain 8. During autophosphorylation,
the Itk SH2 domain directly binds the Itk kinase domain via an interaction that does not involve
the phosphopeptide binding pocket of the Itk SH2 domain, positioning the substrate (Itk SH3
Y180) into the active site of the Itk kinase domain 8. This substrate docking mechanism is
distinct from the processive phosphorylation mechanism that has been described previously
for other kinases, where an SH2 domain located within a kinase molecule itself binds to a
phosphotyrosine site on the substrate facilitating further substrate phosphorylation events 9;
10. While we have shown that the SH2 domain within the known Itk substrates is required for
phosphorylation by Itk 8, the precise docking surfaces on the kinase and SH2 domains are not
known.
We now identify the interaction surface on the Itk SH2 domain that binds directly to the Itk
kinase domain to mediate autophosphorylation of Y180. The docking site on the Itk SH2
domain maps to a surface that involves residues from beta strand D, the AB, EF and BG loops
and is distinct from the classical phosphopeptide binding surface on the Itk SH2 domain. We
demonstrate that mutations within the Itk SH2 domain can disrupt autophosphorylation on Itk
SH3 Y180 in the context of full-length Itk. These results identify an interaction surface on the
Itk SH2 domain that can be added to the growing list of non-canonical interactions mediated
by this multifunctional domain. In addition, we show that a related subset of mutations in the
Btk SH2 domain that cause the immune disorder X-linked agammaglobulinemia (XLA) also
disrupt Btk SH3 autophosphorylation. These mutations map to the same substrate-docking
surface identified for Itk SH2 and suggest a possible mechanistic explanation for this subset
of XLA causing mutations in the Btk SH2 domain.
RESULTS
The SH2 domain of each Tec kinase docks onto the kinase domain via a conserved SH2
surface
With the exception of Txk, each Tec family kinase contains four domains in addition to the
catalytic kinase domain (PH, TH, SH3, SH2; Fig. 1A) and each Tec kinase autophosphorylates
a tyrosine residue within its own SH3 domain (Y180 in Itk) 19; 20; 21. Autophosphorylation
occurs in an intramolecular fashion (in cis) 16 and depends on the presence of the SH2 domain
8. Specifically, Y180 is a very poor substrate for Itk in the context of the isolated Itk SH3
domain, but the same tyrosine is readily phosphorylated by Itk in the context of the larger Itk
SH3-SH2 dual domain substrate 8; 20. This SH2 dependence is explained by a direct docking
interaction between the SH2 domain and the kinase domain for each of the individual Tec
kinases (Itk, Btk and Tec) resulting in proper positioning of the neighboring SH3 domain into
the active site for efficient autophosphorylation 8 (Fig. 1B) .
To determine the residues on the surface of the Itk SH2 domain that are required for substrate
docking, we first evaluated whether each of the Tec family kinase domains (Itk, Btk and Tec)
can phosphorylate the SH3-SH2 fragments derived from the same three kinases (Itk, Btk and
Tec). We expect that if Itk phosphorylates the SH3-SH2 domains of Btk and Tec in addition
to its own SH3-SH2 substrate (and Btk and Tec also phosphorylate all three substrates), then
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the residues on the Itk SH2 domain that mediate substrate docking are likely conserved within
the Tec family.
To test this idea, full-length, purified Itk was separately incubated with the SH3-SH2 domains
of Itk, Btk or Tec in an in vitro kinase assay. The samples were resolved on an SDS-PAGE gel
and western blotted with an anti-phospho Y223 Btk antibody (which has been used previously
to recognize phosphorylation on Btk SH3 Y223, Itk SH3 Y180 and Tec SH3 Y187 8). Full-
length Itk can readily phosphorylate the SH3-SH2 domains of each of the Tec kinases (Itk, Btk
and Tec) (Fig.1C, lanes 4–6). Likewise, full-length Btk and Tec also phosphorylate the SH3-
SH2 domain fragments derived from Itk, Btk and Tec (Fig. 1C, lanes 7–9 and 10–12
respectively). This result indicates that the residues on the Itk SH2 domain that mediate
substrate docking are conserved between Itk, Btk and Tec.
Mapping of the Itk SH2 domain substrate docking surface
In order to identify the conserved docking surface on the Itk SH2 domain, the primary sequence
of this domain was aligned with the SH2 domains of other Tec kinases (Btk, Tec, Txk and
Bmx) as well as two unrelated SH2 domains derived from PI3K and Grb2 which have been
used previously as negative controls 8 (Fig. 1D). Residues that are both surface exposed on the
structure of the Itk SH2 domain (PDB 1LUN) and conserved within the Tec family SH2
domains, but not conserved in the SH2 domains of PI3K and Grb2 were targeted for mutation.
A total of 13 residues were identified by this process that were then mutated to alanine in the
context of the Itk SH3-SH2 domain substrate (boxed residues in Fig. 1D). Mutation of SH2
domain residues that mediate the substrate docking interaction between the SH2 domain and
kinase domain were expected to diminish phosphorylation on Itk SH3 Y180.
As shown in Fig 2A, mutation of the residues E235, Y237, L252, K258, Y292, E308, K309,
G328, L329, R332 and R334 within the Itk SH2 domain significantly diminished
phosphorylation on Itk SH3 Y180. This indicates that these SH2 domain residues are involved
in the substrate docking interaction between the Itk SH2 domain and the Itk kinase domain.
Mutation of Itk Q323 and N325 did not affect Itk SH3 domain phosphorylation suggesting that
these residues do not contribute to substrate docking (Fig. 2A, lanes 15 and 16). To rule out
structural defects in the mutated SH2 domain, circular dichroism (CD) spectra for each of the
mutant substrates was compared with that of the wild-type substrate. The CD spectra of all the
Itk SH3-SH2 mutants are similar to that of the wild-type protein (Fig 2B). Hence, the lack of
phosphorylation on the Itk SH3 domain is not due to general domain unfolding that could be
induced by the Itk SH2 domain mutations but instead is likely due to specific disruption of the
SH2/kinase docking interaction.
We carried out a second round of mutational screening to more broadly survey the Itk SH2
domain surface. Ten residues (indicated by open circles on Fig. 1C) were mutated to alanine
in the context of the Itk SH3-SH2 domain and tested as substrates as before. The Itk SH2
domain residues mutated in the second round of the mutational screen (K242, R246, K251,
E259, R268, T269, S314, N298, D299, and K280) exhibit little or no effect on the level of Itk
SH3 domain phosphorylation when compared to wild type substrate (Fig. 2C). This indicates
that these SH2 residues are not involved in Itk kinase docking. These results contrast the results
from the first round of mutational screening, where almost 90% of the mutated Itk SH2 domain
residues had a significant effect on Itk SH3 domain phosphorylation. The outcome of these
two rounds of mutational screening is consistent with the underlying strategy employed during
the two screens: the more targeted approach in the first screen identified more residues involved
in docking, compared to the more random approach employed in the second round of screening.
Taken together, we have identified a set of residues on the Itk SH2 domain that are required
for docking of the Itk SH2 domain onto the Itk kinase domain and mediating Itk SH3 domain
phosphorylation.
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The Itk SH2 domain substrate-docking surface is distinct from the canonical Itk SH2 domain
ligand binding surface
Mapping the residues that disrupt Itk SH3 domain autophosphorylation (E235, Y237, L252,
Y292, K258, E308, K309, G328, L329, R332 and R334) onto the structure of the unliganded
Itk SH2 domain (PDB ID 1LUN) reveals a mostly contiguous surface involving beta strand D
(βD), the AB, EF and BG loops (red residues in Figs. 3A&B). Three residues (E235, Y237 and
L252) lie outside of the contiguous surface defined by the other eight residues yet clearly have
an effect on substrate phosphorylation when mutated (Fig. 2A). Whether the structure of the
isolated SH2 domain is insufficient to judge the location of these residues (E235 and Y237 are
located on the flexible N terminus) or whether loss of these side chains can allosterically affect
the SH2 docking surface remains to be determined. The residues that are not involved in
substrate docking, based on the mutational data shown in Figure 2C, are scattered over the
surface of the SH2 domain (colored tan in Figs. 3A&B).
The substrate-docking surface on the Itk SH2 domain is largely separate from the canonical
phospholigand binding surface. In Figure 3C, a bound phosphotyrosine containing peptide is
shown on the Itk SH2 structure. It is evident that the phosphotyrosine (pY) itself contacts the
SH2 domain in a region that is removed from the surface that mediates docking onto the Itk
kinase domain. This is consistent with our earlier published results that show that disruption
of phosphopeptide ligand interactions (R265K mutation in the pY binding pocket of the Itk
SH2 domain) has no effect on autophosphorylation of Y180 8. The pY+3 ligand-binding pocket
of the Itk SH2 domain overlaps slightly with the mapped docking surface (Fig. 3C). While
most of the docking surface lies well outside of the pY+3 pocket, Y292 lines the bottom of the
pocket and so it is not entirely clear whether substrate docking and phospholigand binding can
occur simultaneously. Our efforts to directly test the effect of SH2/phosphopeptide binding on
Itk autophosphorylation were thwarted due to toxicity effects of the phosphopeptide on kinase
activity (data not shown).
Mutations in the Itk SH2 domain docking-site disrupt autophosphorylation in full-length Itk
To determine whether Itk SH2 domain mutations disrupt Itk SH3 domain autophosphorylation
in the context of full-length Itk, a subset of the mutations that reduce Y180 phosphorylation
in the context of the isolated Itk SH3-SH2 domain substrate were introduced into the SH2
domain of full-length Itk. These full-length Itk mutants were co-expressed with Lck in Sf9 cells
since Lck, by phosphorylating Y511 in the Itk activation loop, is required to activate Itk 22.
Full length Itk, wild type and mutants, were then purified and incubated in an in vitro kinase
assay and assessed for intramolecular autophosphorylation on Y180 in the SH3 domain by
western blotting 8; 12; 16.
The three different full-length Itk mutants tested (E308A/K309A, G328A/L329A and R332A/
R334A) all showed decreased phosphorylation on Itk SH3 Y180 compared to wild-type full-
length Itk (Fig. 4A). These results should be interpreted cautiously since reduced
autophosphorylation on Y180 in the context of full-length Itk could be due to several factors
including: (1) disruption of Itk SH2 domain substrate docking, (2) reduced phosphorylation
on the kinase domain activation loop tyrosine (Y511) which is required for Itk kinase activity
22, and/or (3) reduced/altered kinase activity of the full-length Itk mutant 12. These properties
were assessed for each of the full-length Itk mutants to establish whether substrate docking is
indeed mediated by the identified surface residues in the context of full length Itk.
The Itk G328A/L329A and R332A/R334A double mutants showed reduced
autophosphorylation on Y180, yet they both also exhibited reduced phosphorylation on Y511
(Fig. 4A). Since a reduction in the phosphorylation level of Y511 reduces Itk kinase activity
(Fig. 4B)23, the loss of Y180 autophosphorylation for these two mutants cannot be fully
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attributed to disruption of SH2 mediated docking. Thus, while both the G328A/L329A and the
R332A/R334A double mutants are important for substrate docking and autophosphorylation
on Y180 in the context of the Itk SH3-SH2 domain fragment, in the context of full-length Itk
these mutations have additional effects that account for at least part of the observed reduction
in autophosphorylation. Indeed, the effect of certain Itk SH2 domain mutations on Y511
phosphorylation indicates an involvement of the Itk SH2 domain in mediating Y511
phosphorylation by Lck (Joseph & Andreotti, unpublished data).
The E308A/K309A double mutant exhibits reduced autophosphorylation on Y180 compared
to wild-type full-length Itk, without loss of phosphorylation on Y511 (Fig. 4A) indicating that
these mutations selectively affect SH2 docking. To further confirm that the reduced
autophosphorylation levels are not due to impaired kinase activity of the mutant, the kinetic
parameters of the full length Itk E308A/K309A double mutant were compared to those of wild-
type full-length Itk. The Km and kcat values of Itk E308A/K309A double mutant are
indistinguishable from those of wild-type Itk (Fig. 4C, D and F). We additionally tested whether
the E308A/K309A double mutation has an effect on the Itk SH2 domain ligand binding
function. Phosphopeptide ligand binding affinity of the Itk SH2 E308A/K309A double mutant
was measured using NMR spectroscopy and compared with that of wild-type Itk SH2 domain.
As shown in Fig. 4E, the affinity of the Itk SH2 E308A/K309A double mutant for the SLP76
phospho-peptide ligand is comparable to that of the wild-type Itk SH2 domain (Dissociation
constant, (Kd) of 0.48 ± 0.06 mM and 0.38 ± 0.04 mM, respectively). Thus, the E308A/K309A
mutation does not affect either Km or kcat for the kinase domain nor does it alter phospholigand
binding behavior of the SH2 domain and so the loss of autophosphorylation on Y180 in the
full-length Itk E308A/K309A double mutant can be interpreted as causing a specific disruption
of the direct SH2 domain docking that mediates Y180 autophosphorylation. Taken together,
these data provide evidence for a specific substrate docking role for the Itk SH2 domain during
autophosphorylation of Y180 in the SH3 domain of full-length Itk.
The Btk SH2 domain XLA mutations affect SH2 mediated substrate docking
Genetic mutations in the Tec family kinase, Btk, are correlated with a specific B cell
immunodeficiency in humans: X-linked agammaglobulinemia (XLA) 24; 25. XLA causing
mutations have been identified throughout the entire Btk molecule including the Btk SH2
domain 24. To date, XLA causing mutations have been identified at 43 unique positions in the
97 amino acid Btk SH2 domain 24. Examination of these XLA causing mutations in the Btk
SH2 domain suggests classification into several categories: (1) stop codon mutations resulting
in premature termination of translation and giving rise to truncated protein products, (2)
mutations causing an amino acid change in the classical phosphopeptide ligand binding pocket
of the SH2 domain that alter ligand binding in a deleterious fashion, (3) mutations causing an
amino acid change in the core of the SH2 domain that disrupt the structural integrity of the
SH2 domain and (4) mutations causing an amino acid change on the surface of the SH2 domain
that are not close to the phospholigand binding site and therefore are not readily explained by
the known functions of the Btk SH2 domain. We focused on this last category of XLA causing
mutations (14 in total) and evaluated whether these SH2 mutations might disrupt
autophosphorylation on Btk SH3 Y223 (corresponds to Y180 in Itk) by altering SH2 mediated
substrate docking to the Btk kinase domain.
Fourteen specific Btk SH2 XLA causing mutations (indicated in Fig. 1D) were individually
introduced into the Btk SH3-SH2 substrate to test the extent to which these SH2 residues
mediate Y223 phosphorylation in an in vitro kinase assay using full-length Btk as the enzyme.
Of the 14 Btk SH2 residues targeted for mutation, three mutants (G302R, Y361D and H362R)
resulted in expression of insoluble protein in bacteria and were therefore not tested further. As
shown in Fig. 5A, six Btk SH2 XLA mutations tested (Y334S, L358F, H364D, S371P, R372G
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and K374N; lanes 7–8, 11–12, 13–14, 23–24, 25–26, 27–28) decrease Btk SH3 Y223
phosphorylation compared to the wild type Btk SH3-SH2 substrate. To ensure that the Btk
SH2 domain XLA mutations do not disrupt the structural integrity of the Btk SH2 domain, we
compared the CD spectra of the mutants that showed the most significant decrease in Btk SH3
domain phosphorylation (H364D, S371P and R372G) with that of the wild-type Btk SH3-SH2
protein. The CD spectra of all three mutants are similar to that of the wild-type protein (Fig.
5B), suggesting that the mutations do not cause major structural rearrangements in the protein.
Thus, in analogy to the Itk results shown in Figure 2A, the decrease in Btk SH3 domain
phosphorylation in the Btk SH2 H364D, S371P and R372G mutants is likely due to the
disruption of Btk SH2 domain mediated kinase docking.
To further characterize the XLA causing mutations in the Btk SH2 domain, we tested the effect
of these mutations on phospho-peptide ligand binding by NMR. The R372G mutant was not
stable at concentrations required for NMR spectroscopy and hence its phosphopeptide ligand
binding affinity was not measured. The phosphopeptide ligand affinities of Btk H364D and
S371P mutants are nearly identical to each other (Dissociation constant, (Kd) of 0.50 ± 0.20
mM and 0.60 ± 0.11 mM respectively) and to that of the wild-type protein (Kd of 0.45 ± 0.04
mM) (Fig. 5C). Hence, the Btk H364D and S371P mutations do not significantly affect the
phospho-peptide ligand binding property of the Btk SH2 domain (Fig. 5C). Notably, the Btk
SH2 XLA mutations that disrupt Btk Y223 phosphorylation map to the base of the Btk SH2
domain BG loop, which corresponds to the same region of the Itk SH2 domain that mediates
substrate docking and Itk autophosphorylation (Fig. 5D). While the observed connection
between the Btk XLA causing mutations and disruption of substrate docking is compelling,
further experiments are clearly needed to confirm a link between a protein interaction interface
and disease.
Structural model of Itk during autophosphorylation
While the docking surface on the Itk SH2 domain has been identified in this study, the
complimentary docking surface on the kinase domain remains unknown. Introducing mutations
into the Itk kinase domain to identify the docking site for the SH2 domain will require careful
characterization since point mutations in the kinase domain may drastically affect catalytic
activity without affecting SH2/kinase docking 12. In the meantime, we have generated a
preliminary model (Fig. 6A) for substrate docking in the context of Itk autophosphorylation
that provides a structural context to consider the results presented here and provides guidance
as we move toward mutagenesis of the Itk kinase domain itself. In developing the model we
took into consideration two previously published observations: (1) autophosphorylation of
Y180 in the Itk SH3 domain occurs via an intramolecular interaction (in cis), where the Itk
kinase domain phosphorylates the SH3 domain within the same polypeptide chain 16 and (2)
contact between W355 in the Itk SH2-kinase linker and M410 in the C-helix of the Itk kinase
domain is critical for Itk kinase activity 12. We have previously reported a model of the Itk
SH3 domain bound to the Itk kinase domain during SH3 Y180 autophosphorylation 16. To
generate this model, the Itk kinase domain was aligned with the Insulin receptor kinase (Irk)
domain within the Irk:peptide substrate complex 26, and Y180 within the Itk SH3 domain was
aligned with the tyrosine of the Irk peptide substrate in the active site (Fig. 6A). Once aligned,
the Itk SH3 domain fits well into the Itk kinase active site and no further structural
rearrangements are necessary.
In the primary sequence of full length Itk, the SH2 domain is tethered to the Itk SH3 domain
at its N-terminus and to the SH2-kinase linker at its C-terminus (Fig. 6A). The Itk SH2 domain
was therefore docked onto the Itk SH3/Itk kinase complex to a position that satisfies the length
and steric requirements of the covalent linkers between domains. In the model, the linkers were
assumed to adopt extended conformations and W355 in the SH2-kinase linker is maintained
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in a position that is proximate to M410 in the kinase domain 12 (Fig. 6A). The orientation of
the Itk SH2 domain was determined by maximizing contacts between the Itk SH2 residues
identified in this study (Fig. 3) and the kinase domain. The resulting model shown in Figure
6A represents one plausible location for the Itk SH2 domain on the Itk kinase domain, the
details of which remains to be verified experimentally. In this model, the Itk SH2 domain can
contact residues from both the N- and C-terminal lobes of the Itk kinase domain. As well, a
phosphopeptide may be placed into the ligand-binding pocket of the SH2 domain in this model
27 without steric hindrance suggesting that the ligand-binding surface of the Itk SH2 domain
remains largely accessible during autophosphorylation.
In addition to the location of SH2 docking on the Itk kinase domain, the model predicts a
relative orientation between the Itk SH3 and SH2 domains during autophosphorylation. To
examine the dual domain SH3-SH2 fragment further, we extracted this region from the modeled
structure and, as expected, find that the SH2 side chains that mediate contacts to the kinase
domain (Fig. 3) are located on the same side as Y180 within the SH3 domain (Fig. 6B). Notably,
we find that the Itk SH3-SH2 domain fragment in the modeled structure is remarkably similar
to the previously reported crystal structure of the corresponding Lck SH3-SH2 dual domain
fragment 28 (Fig 6B). Specifically, the relative orientations between the SH3 and SH2 domains
in the experimentally solved Lck SH3-SH2 structure and in the modeled Itk arrangement of
these domains are almost the same. While the model generated here is certainly useful to
visualize how SH2 docking might be mediating Itk autophosphorylation, future mapping
experiments to identify the precise binding site on the kinase domain, NMR solution studies
to examine domain orientations and crystal structures of the Itk kinase/substrate complex will
ultimately be needed to reveal the details of this interaction.
DISCUSSION
SH2 domains are present in hundreds of different signaling proteins and have been studied
extensively since they were first recognized as phosphotyrosine-binding domains 29. Typically,
the role of a specific SH2 domain in a given signaling cascade is evaluated by a standard
mutation that renders the phosphotyrosine binding pocket of the SH2 domain inactive. In this
vein, it has been demonstrated previously that the SH2 domains of the Tec kinases are required
for proper localization and functioning of this family of kinases during immune cell signaling
30; 31; 32; 33. For example, binding of Itk via its SH2 domain to the phospho-SLP76/LAT
complex is essential for the propagation of T cell receptor signaling 34; 35; 36. Mutation of the
conserved arginine (R265) in the Itk SH2 domain leads to reduced association of full length
Itk with LAT and reduced transphosphorylation of Itk, in turn leading to severely reduced
kinase activity 36. Classical phosphotyrosine binding by SH2 domains is clearly a critical
component of SH2 mediated signaling.
It is evident that there are also various signal transduction pathways that are mediated by non-
phosphotyrosine dependent SH2 interactions 37; 38; 39; 40; 41; 42; 43; 44. The Itk SH2 substrate-
docking surface identified in this study contains residues that are distinct from those that
mediate classical phosphotyrosine recognition (Fig. 3C) 27 adding to the growing list of
alternative SH2 mediated interactions. Whether some SH2 domains, such as that of Itk, might
simultaneously mediate more than one protein-protein interaction remains to be determined.
In fact, it should be noted that the autophosphorylation event under investigation here is likely
a transient conformational state rather than a stable configuration.
Our model of Itk autophosphorylation (Fig. 6A) suggests that the SH2 domain can mediate
Y180 phosphorylation while also retaining binding to at least the phosphotyrosine of a
phospholigand in the signaling complex. Hence, it is possible that Itk autophosphorylation
occurs while Itk is bound to the phospho-SLP76/LAT complex 34; 36; 45; 46 or alternatively,
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autophosphorylation might facilitate displacement of Itk from the SLP76/LAT complex by
competing with binding to the pY+3 pocket. Ultimately, understanding the precise order in
which all of these signaling steps take place and the significance of each in terms of propagating
or dampening signals that emanate from the T cell receptor will require more investigation.
Substrate docking within the Tec kinase family can be compared to another non-receptor
tyrosine kinase for which substrate docking has been described. Csk phosphorylates a tyrosine
in the C-terminal tail of Src via a direct substrate docking interaction 5; 6; 7. Mutational studies,
as well as a recent crystal structure of the Csk/Src enzyme/substrate complex, have revealed
the precise surfaces on both enzyme (Csk) and substrate (Src) that mediate this interaction 5;
6; 7. There is no involvement of an SH2 domain; rather the Csk kinase domain phosphorylates
the Src tail via direct interaction with a subset of residues presented on the C-terminal lobe of
the Src kinase domain surface 5; 6; 7. Regardless of the accuracy of our modeled docking
interface (Fig. 6A), it appears that the Csk/Src docking interface is distinct from the Itk SH2/
kinase interface both in the nature of the substrate domain required for docking and in the
location of the docking site on the kinase domain itself. The intramolecular nature of the Itk
docking interaction and the covalent constraints imposed by the linkers between domains mean
that the Itk SH2 domain is not likely to occupy the same position on the Itk kinase domain as
the Src substrate does on the Csk kinase domain.
For decades the phosphotyrosine binding function of SH2 domains has been recognized as a
critical component of many signaling pathways. What then is the role of non-classical
interactions such as that described here for the Itk SH2 domain? An immune dysregulation
syndrome following Epstein-Barr virus infection in girls has recently been linked to a single
amino acid change in the Itk SH2 domain that lies outside of the classical phospholigand
binding site 47 but is central to the SH2 docking surface defined here. Specifically, a missense
mutation that results in substitution of R334 (mouse numbering) with tryptophan leads to a
phenotype consistent with that observed in Itk deficient mouse models 47. As illustrated in
Figure 2 and Figure 4, we have shown that loss of the R334 sidechain in the Itk SH2 domain
reduces the phosphorylation levels of both Y511 and Y180, which would render Itk inactive.
Interestingly, mutation of precisely the same site in the SH2 domain of SAP causes X-linked
lymphoproliferative disease 48 and we report here that a subset of XLA causing mutations in
the Btk SH2 domain (including K374N, the site corresponding to R334 in Itk) significantly
alter Btk autophosphorylation efficiency (Fig. 5).
While it is tempting to speculate that these mutations disrupt important non-canonical
interactions of the SH2 domains required for activation and signaling, specific studies that
examined the disease-causing SH2 mutations in Itk and SAP (R334W for Itk and Q99P in
SAP) conclude that these particular mutations lead to protein instability and resulting
deficiencies in enzyme levels are the cause of the severe phenotype 47; 48. In contrast, protein
instability has not been observed for the corresponding site in Btk that carries the XLA causing
mutation, K374N 49. In fact, consistent with our finding that this XLA causing mutation reduces
Btk autophosphorylation in vitro (Fig. 5), these authors report that the K374N mutation in the
SH2 domain of full length Btk shows significantly reduced phosphorylation on Y223 and fails
to trigger calcium flux in response to IgM crosslinking 49. The SH2 mediated docking
interaction defined here for Itk and Btk begins to provide mechanistic insight into why
particular mutations in the SH2 domain that appear remote from the phospholigand binding
site can nevertheless adversely affect the signaling function of these immune kinases. Thus,
while acknowledging that the links between specific mutations and specific diseases likely
arise from multiple phenomena, it is nevertheless interesting to consider the importance of non-
classical domain functions and the potential for mutations in these less well characterized
regions to cause disease.
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EXPERIMENTAL PROCEDURES
Materials
The Itk SH2 phospho-peptide ligand (phospho-SLP76 peptide, ADpYEPP) and the Btk SH2
phospho-peptide ligand (GDGpYEEISPLLL11) were obtained from GenScript. Biotin labeled
Peptide-B (Aminohexanoyl biotin-EQEDEPEGIYGVLF-NH2) was obtained from AnaSpec
Inc. The peptide concentration and sequences were confirmed by amino acid analysis (Keck
Biotechnology Resource Laboratory, Yale) and MALDI-TOF MS (Iowa State University
Protein Facility) respectively. The anti-pY223 Btk antibody (corresponding to Itk pY180 and
Tec pY187) and anti-pY551 Btk antibody (corresponding to Itk pY511) were kind gifts from
Dr Owen Witte.
Constructs
The baculoviral expression constructs for full-length Itk, Btk and Tec have been described
previously 12. The full-length baculoviral construct for Lck was a kind gift from Dr. Leslie
Berg. The bacterial expression constructs for the Btk and Tec SH3-SH2 domain constructs
have been described elsewhere 8. The C-terminally Myc-His tagged Itk SH3-SH2 domain was
created by PCR amplifying the Itk SH3-SH2 domain (residues 171–338) and cloning it into
the pTrcHis2-TOPO vector (Invitrogen). All mutations were introduced by using the site
directed mutagenesis (SDM) kit (Stratagene). All constructs were verified by sequencing at
the Iowa State DNA synthesis and sequencing facility.
Protein expression and purification
Baculoviral constructs were expressed and purified from Sf9 cells as described previously 12.
The bacterial expression constructs for the His-tagged Itk, Btk and Tec SH3-SH2 domains
were transformed into BL21 cells (Novagen). The cells were grown in LB media to an
OD600nm of 0.7 and induced with 1 mM IPTG at 16 °C overnight. The cells were harvested,
re-suspended in lysis buffer (50 mM KH2PO4, pH 8.0, 150 mM NaCl, 20 mM imidazole, 0.5
mg/ml lysozyme) and frozen overnight at −80°C. The cell pellets were thawed and incubated
on ice for 15 min with 1 mM PMSF and 5000 Units of DNase I (Sigma). The lysate was spun
at 16K for 1 hour at 4°C and the proteins were loaded onto the Nickel-NTA resin (Qiagen),
washed with wash buffer I (50 mM KH2PO4, pH 8.0, 150 mM NaCl, 40 mM imidazole),
followed by wash buffer II (50 mM Hepes, pH 7.5, 150 mM NaCl). The proteins were then
eluted in elution buffer (50 mM Hepes, pH 7.5, 150 mM NaCl, 250 mM imidazole).
Kinase assays and western blotting
In vitro kinase assays were performed by incubating full-length Itk, Btk or Tec with their
respective substrate in a kinase assay buffer (50 mM Hepes pH 7.0, 10 mM MgCl2, 1 mM
DTT, 1 mg/ml BSA, 1 mM Pefabloc and 200 µM ATP) at 25 °C for one hour. The samples
were boiled, separated by SDS-PAGE and western blotted with the Anti Btk phosphoY223
antibody, anti-FLAG (Sigma) antibody or anti-Myc (Invitrogen) antibody as described
previously 8. Kinetic parameters for the full-length wild-type and mutant Itk are derived using
radioactive assays that have been described previously 12.
Circular dichroism (CD) Spectra
CD measurements of the Itk SH3-SH2 domains and Btk SH3-SH2 domains were performed
on a Jasco J-715 CD spectropolarimeter (Jasco Inc.) in the far UV region (190–260 nm) at 25
°C. Samples were prepared in 10 mM KH2PO4, pH 7.4, at a concentration of 8 µM. CD spectra
were recorded at a scanning rate of 50 nm / min with a spectral bandwidth of 2 nm and response
times of 2 msec. Ten accumulations were acquired and the results were averaged. After
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background subtraction, all the CD data were converted from mdegree into molar residue
ellipticity (deg cm2 dmol−1).
NMR titrations
NMR Spectra were acquired using a Bruker DRX500 spectrometer operating at 1H frequency
of 499.867 MHz. All spectra were obtained at 298K. 1H and 15N chemical shifts were externally
referenced to 2,2-dimethyl-2-silapentane-5-sulfonate sodium salt (DSS) in identical buffer.
NMR titrations were carried out as described 13; 14; 15; 16. All protein samples were prepared
in 50 mM sodium phosphate (pH 7.2), 75 mM NaCl, 2 mM DTT, 0.02% (w/v) NaN3. Unlabeled
phospho-peptide ligand was added stepwise to 15N-labeled protein and each step was
monitored by acquiring a 2D 1H-15N HSQC spectrum 17. The changes in 1H and 15N chemical
shifts were quantified using the formula 18:
The dissociation constants were derived from binding curves using the Matlab (version 5.3.1,
The Mathworks Inc.) suite of programs by plotting Δδave versus ligand concentration.
Abbreviations
Itk, Interleukin-2 tyrosine kinase; Btk, Bruton’s tyrosine kinase; SH2, Src homology 2; SH3,
Src homology 3; XLA, X-linked agammaglobulinemia.
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Figure 1. Tec kinases mediate SH3 domain autophosphorylation via a conserved surface on the
SH2 domain
(A) Domain architecture of full-length Itk (residues 1–619), with a Pleckstrin homology (PH),
Tec homology (TH), SH3, SH2 and kinase domain. The autophosphorylation site (Y180) is
located within the Itk SH3 domain. (B) Schematic representation of Itk SH3 domain
autophosphorylation. Autophosphorylation on Y180 in the SH3 domain occurs ‘in cis’ and a
direct binding interaction between the Itk SH2 domain and the Itk kinase domain is necessary
for Itk SH3 domain phosphorylation 8; 16. It should be noted that full length Itk or single
polypeptide fragments of Itk that contain both the kinase domain and the Y180 containing SH3
domain (SH3-SH2-kinase) exclusively autophosphorylate in cis. Nevertheless, the smaller Itk
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SH3-SH2 domain fragment can be phosphorylated by Itk in trans as shown in (C). (C) Itk, Btk
and Tec can each phosphorylate the SH3 domain of Itk, Btk or Tec. Full-length Itk (lanes 4, 5
and 6), full-length Btk (lanes 7, 8 and 9) or full-length Tec (lanes 10, 11 and 12) were incubated
with the substrate SH3-SH2 domain construct of Itk (lanes 4, 7 and 10), Btk (lanes 5, 8 and
11) or Tec (lanes 6, 9 and 12) in an in vitro kinase assay buffer at RT for one hour. The samples
were separated by SDS-PAGE and western blotted with an anti-Btk phospho-Y223 antibody
(used to detect phosphorylation on Itk Y180, and Tec Y187) or an anti-FLAG antibody to
detect enzyme levels. Ponceau S stain of the membrane in the bottom panel indicates substrate
levels. Lanes 1, 2 and 3 are the no enzyme controls for the SH3-SH2 domains of Itk, Btk and
Tec, respectively. The data shown is representative of at least three independent experiments.
(D) Sequence alignment of the Itk SH2 domain with the SH2 domains of other Tec family
members Btk, Tec, Txk and Bmx, and two unrelated SH2 domains: phosphoinositide 3-kinase
(PI3K) and Grb2. The secondary structure elements derived from the structure of the Itk SH2
domain are indicated by arrows (β strand) and boxes (α helix) above the sequence. All SH2
domain residues that have been mutated in this study are boxed or indicated by open circles
above the sequence. The Btk XLA mutations tested in this study are indicated by asterisks.
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Figure 2. Mutations in the Itk SH2 domain disrupt phosphorylation on Itk SH3 Y180
(A) Surface residues on the Itk SH2 domain that are conserved within the Tec family (boxed
residues in Fig.1D) but different from the corresponding residues in the SH2 domains of PI3K
and Grb2 were mutated in the context of Myc-tagged Itk SH3-SH2 domain. These mutants
(lanes 1, 3, 5, 7, 9, 11, 13, 15, 17 and 19: one µM substrate; lanes 2, 4, 6, 8, 10, 12, 14, 16, 18
and 20: five µM substrate) were incubated with full-length FLAG-tagged Itk in an in vitro
kinase assay at room temperature for one hour. The samples were separated by SDS-PAGE
and western blotted with an anti-Btk phospho-Y223 antibody, anti-Myc antibody (to detect
substrate levels) or an anti-FLAG antibody (to detect enzyme levels). Lanes 1 and 2 are the no
enzyme controls. The data shown is representative of at least three independent experiments.
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The phosphorylation level of each mutant SH3-SH2 substrate (indicated by arrow) is compared
to that of wild type substrate. Reduced Y180 phosphorylation for a mutant compared to wild
type suggests a disruption of the SH2 mediated docking interaction. (B) The Itk SH2 domain
docking mutations do not cause major structural changes in the Itk SH2 domain. Circular
Dichroism (CD) spectra of Itk mutant substrates overlaid with that of the wild-type protein
show no major changes in secondary structure. (C) Additional Itk SH2 domain surface residues
were mutated in a second round of screening (indicated by open circles in Fig. 1D) and tested
as in Fig. 2A. Lanes 1–12 were probed using the anti-Btk phospho-Y223 antibody from Dr.
Owen Witte while lanes 13–20 were probed using the anti-Btk phospho-Y223 antibody from
Invitrogen.
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Figure 3. Mapping of the Itk SH2 domain residues involved in Itk kinase docking onto the domain
structure
(A) The Itk SH2 domain residues that are mutated in this study are mapped onto the structure
of the Itk SH2 domain (ribbon structure shown in cyan, PDB ID 1LUN). Based on the data
shown in Fig. 2, residues that, upon mutation, disrupt autophosphorylation on SH3 Y180 are
shown in red. The residues that, upon mutation, have no effect on Y180 phosphorylation are
in tan. The docking interface on the Itk SH2 domain clusters primarily on one side of the
molecule (two views are shown) and involves residues from the AB, BG and EF loops as well
as the base of the βD strand. (B) Surface representation of the same structural information
shown in (A). The red surface area maps the residues that, when mutated to alanine, diminish
Y180 phosphorylation in the context of the SH3-SH2 substrate and the tan color indicates
mutations that have no effect on Y180 phosphorylation. (C) Surface rendering of the Itk SH2
domain bound to its classical phosphotyrosine containing peptide 27. The phosphopetide is
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shown in orange with the phosphotyrosine (pY) and proline residue in the pY+3 position
included as sticks and labeled. The red surface indicates those residues mapped by mutation
that mediate phosphorylation of Y180. This substrate docking surface is circled on both
structures and the views of the structure differ by 90°. Y292 (labeled on structure) is the only
docking residue that is within the pY+3 binding pocket. All structure figures were generated
using PyMol 50.
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Figure 4. Mutations within the Itk SH2 domain disrupt autophosphorylation on Itk SH3 Y180
within full-length Itk
(A) FLAG-tagged Itk full-length wild-type, Y180F (negative control), E308A/K309A,
G328A/L329A, or R332A/R334A mutants are expressed in Sf9 cells along with full-length
wild-type Lck. Itk is purified using an anti-FLAG resin and the proteins are then incubated at
room temperature in an in vitro kinase assay buffer and western blotted with an anti-Btk
phosphoY223 antibody, anti-pY511 antibody and anti-Itk antibody. Y180 phosphorylation
levels are reduced for all four mutant substrates compared to wild type substrate (top panel).
(B) Initial velocity (Vi) of wild type, full length Itk (lane 1, WT), G328A/L329A (lane 2) and
R332A/R334A (lane 3) mutants are measured using Peptide B as substrate. Lane 4 is the no
enzyme control. (C and D) The E308A/K309A double mutation has no significant effect on
full-length Itk kinase activity. Itk substrate (Peptide B and ATP respectively) curves of WT
full-length Itk (filled triangles) and the full length Itk E308A/K309A mutant (open squares)
were fit to the Michaelis-Menten equation using GraphFit to obtain the kinetic parameters
reported in (F). (E) Itk SH2 E308A/K309A double mutation has no effect on phospho-peptide
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binding. An initial concentration of 300 µM of either 15N-labeled WT Itk SH2 (open circles)
or 15N-labeled SH2 E308A/K309A mutant (filled circles) was titrated with increasing
concentration of phospho-SLP76 peptide (ADpYEPP). 1H-15N HSQC spectra were obtained
upon addition of each aliquot of ligand. Binding curves were generated by plotting the
normalized concentration dependence of amide 1H chemical shifts for resonances
corresponding to Itk K242, V275, C288, K290, Y292, I294, K295, E296, Y305 and A307. (F)
The kinetic parameters for wild-type Itk and Itk E308AK309A. The kinetic parameters for
wild-type Itk have been reported previously12.
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Figure 5. XLA causing mutations within the Btk SH2 domain disrupt autophosphorylation on Y223
in the Btk SH3 domain
(A) A subset of the XLA causing mutations that have been identified within the Btk SH2
domain were introduced into the Btk SH3-SH2 domain fragment. These mutants (lanes 1, 3,
5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 and 27: one µM SH3-SH2 substrate; lanes 2, 4, 6, 8, 10,
12, 14, 16, 18, 20, 22, 24, 26 and 28: five µM SH3-SH2 substrate) were incubated with full-
length FLAG-tagged Btk in an in vitro kinase assay at room temperature for one hour. The
samples were separated by SDS-PAGE and western blotted with an anti-Btk phospho-Y223
antibody or an anti-FLAG antibody (to detect enzyme levels). Coomassie staining of the gel
shows the substrate levels. Lanes 1 and 2 are the no enzyme controls. The data shown is
representative of at least three independent experiments. A subset of these XLA causing
mutations result in a reduction of Y223 phosphorylation (lanes 7, 8, 11–14, 23–28). (B) The
CD spectra of wild-type Btk SH3-SH2 superimposed with spectra of the Btk SH2 XLA mutants
(H364D, S371P and R372G). (C) Btk SH2 XLA H364D and S371P mutations do not affect
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phospho-peptide binding. An initial concentration of 250 µM of either 15N-labeled WT Btk
SH2 (open circles), Btk SH2 H364D (filled circles) or Btk SH2 S371P (open squares) were
titrated with increasing concentration of phospho-peptide (GDGpYEEISPLLL). 1H-15N
HSQC spectra were obtained upon addition of each aliquot of ligand. Binding curves were
generated by plotting the normalized concentration dependence of amide 1H chemical shifts
for resonances corresponding to Btk Y279, R288, E292, R307, T316, Y334, C337, S338, A347,
K349, L373 and V377. (D) The Btk SH2 XLA mutations that disrupt Btk SH3 domain
autophosphorylation map to the same surface as that identified on the Itk SH2 domain. Btk
SH2 XLA causing mutations were mapped onto the Btk SH2 domain (shown in grey on left,
PDB ID 2GE9). Mutations that disrupt Btk autophosphorylation are represented as sticks in
green and labeled and those residues that do not diminish phosphorylation are shown as tan
sticks. The color scheme highlighting the docking interface on the Itk SH2 domain is the same
as that described in Figure 3. The substrate docking surfaces on both Btk and Itk SH2 domains
are circled and the Btk and Itk SH2 domains are shown in the same orientation.
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Figure 6. Model of the Itk kinase domain docked with the Itk SH2 domain
(A) Two views of the structural model showing a possible docking configuration of the Itk
SH2 domain with the Itk kinase domain during SH3 autophosphorylation. The domain structure
of the SH3-SH2-Kinase fragment of Itk is shown as a schematic. The Itk kinase domain
structure (shown in blue, PDB ID 1SNX) was aligned with the structure of the substrate-bound
insulin receptor kinase domain (PDB ID 1IR3). For clarity, the insulin receptor kinase substrate
bound structure is not shown. In the view on the left, the kinase domain is oriented with the
active site facing the viewer and the N- and C-lobes are labeled. The Itk SH3 domain (black
ribbon) was docked into the Itk kinase domain active site by superimposing Itk Y180
(represented by sticks in red) with the tyrosine residue of the insulin receptor kinase substrate
as previously described 16. The docked SH2 domain is orange and the residues identified by
mutagenesis are depicted in green. The SH2-kinase linker is labeled and shown with a broken
brown line and the SH3-SH2 domain linker is labeled and shown as a broken yellow line. W355
and M410 (residues required for Itk kinase activity) are labeled. The red arc with the double-
headed arrows is to indicate that this model represents one location within a range of possible
locations for the Itk SH2 domain on the Itk kinase domain. To illustrate the accessibility of the
SH2 phospholigand binding site during autophosphorylation, a bound phosphopeptide is added
(based on PDB ID 2ETZ) to the model and depicted in cyan; the pY and pY+3 residues are
labeled. In the view on the right, the side chains of the Itk SH2 domain that, upon mutation,
disrupt phosphorylation of Y180 are labeled. (B) Structural comparison of the Lck SH3-SH2
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dual domain structure (shown in tan, PDB ID 1LCK) solved by crystallography (right) 28, with
the Itk SH3-SH2 dual domain fragment (left) extracted from the model of autophosphorylation
shown in (A). The Itk SH2 residues that mediate Y180 phosphorylation are depicted in green
and Y180 is red. The standard secondary structural elements for the SH3 and SH2 domains are
indicated to illustrate the similarity in the relative domain orientations.
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